<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04921384</url>
  </required_header>
  <id_info>
    <org_study_id>19140A</org_study_id>
    <nct_id>NCT04921384</nct_id>
  </id_info>
  <brief_title>Eptinezumab as Preventive Treatment of Migraine in Adults With Migraine</brief_title>
  <acronym>Sunrise</acronym>
  <official_title>Interventional, Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate Efficacy and Safety of Eptinezumab for the Preventive Treatment of Migraine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>H. Lundbeck A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>H. Lundbeck A/S</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the efficacy of eptinezumab to prevent migraine in patients with chronic&#xD;
      migraine&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an interventional, multi-regional, multi-site, randomized, double-blind,&#xD;
      placebo-controlled Phase III study, to confirm the efficacy and safety of eptinezumab in&#xD;
      patients with chronic migraine who are eligible for preventive treatment.&#xD;
&#xD;
      Patients will be randomly allocated to one of three treatment groups: eptinezumab 300 mg,&#xD;
      eptinezumab 100 mg, or placebo.&#xD;
&#xD;
      Patients in Japan will continue in a separate extension study. For patients outside Japan,&#xD;
      the double-blind, placebo-controlled treatment period will be followed by an extension period&#xD;
      where all patients will receive active treatment to further assess the safety and&#xD;
      tolerability of eptinezumab.&#xD;
&#xD;
      The total study duration from the Screening Visit to the Safety Follow-up Visit is&#xD;
      approximately 24 weeks and includes a Screening Period (28-30 days), a Placebo-controlled&#xD;
      Period (12 weeks), and a Safety Follow-up Period (8 weeks).&#xD;
&#xD;
      For patients outside Japan, the total study duration from the Screening Visit to the Safety&#xD;
      Follow-up Visit is approximately 36 weeks and includes a Screening Period (28-30 days), a&#xD;
      Placebo-controlled Period (12 weeks), an Extension Period (12 weeks) and a Safety Follow-up&#xD;
      Period (8 weeks).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 29, 2021</start_date>
  <completion_date type="Anticipated">July 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in the number of monthly migraine days (MMDs) (Weeks 1-12)</measure>
    <time_frame>Weeks 1-12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response: ≥50% reduction from baseline in MMDs (Weeks 1-12)</measure>
    <time_frame>Weeks 1-12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response: ≥75% reduction from baseline in MMDs (Weeks 1-4)</measure>
    <time_frame>Weeks 1-4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response: ≥75% reduction from baseline in MMDs, (Weeks 1-12)</measure>
    <time_frame>Weeks 1-12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Migraine rate on the day after dosing</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response: ≥50% reduction from baseline in monthly headache days (MHDs) (Weeks 1-12)</measure>
    <time_frame>Weeks 1-12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the number of MHDs (Weeks 1-12)</measure>
    <time_frame>Weeks 1-12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response: ≥75% reduction from baseline in MHDs (Weeks 1-4)</measure>
    <time_frame>Weeks 1-4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in rate of migraines with severe pain intensity (Weeks 1-12)</measure>
    <time_frame>Weeks 1-12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in rate of headaches with severe pain intensity (Weeks 1-12)</measure>
    <time_frame>Weeks 1-12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the number of MMDs with use of acute medication (Weeks 1-12)</measure>
    <time_frame>Weeks 1-12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Impression of Change (PGIC) score at week 12</measure>
    <time_frame>Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Most Bothersome Symptom (MBS) score at Week 12, as measured relative to Screening</measure>
    <time_frame>Screening to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to Week 12 in the Headache Impact Test (HIT-6) score</measure>
    <time_frame>Baseline to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to Week 12 in the Migraine-Specific Quality of Life (MSQ v2.1) sub-scores (Role Function-Restrictive, Role Function-Preventive, Emotional Function)</measure>
    <time_frame>Baseline to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to Week 12 in the Health-Related Quality of Life (EQ-5D-5L) Visual Analogue Scale (VAS) score</measure>
    <time_frame>Baseline to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health Care Resources Utilization (HCRU)</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Migraine-specific healthcare resource utilization information will be collected in terms of outpatient health care professional visits, emergency room visits, hospital admissions, as well as duration of hospital stays.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to Week 12 in the Work Productivity and Activity Impairment Questionnaire: Migraine (WPAI:M) sub-scores (Absenteeism, Presenteeism, Work productivity loss, Activity impairment)</measure>
    <time_frame>Baseline to Week 12</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">513</enrollment>
  <condition>Migraine</condition>
  <arm_group>
    <arm_group_label>Eptinezumab 300 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Double-Blind Treatment Phase (at baseline): 300 mg eptinezumab by intravenous (IV) infusion.&#xD;
For patients outside Japan, at week 12: 100 or 300 eptinezumab by IV infusion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Eptinezumab 100 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Double-Blind Treatment Phase (at baseline): 100 mg eptinezumab by IV infusion.&#xD;
For patients outside Japan, at week 12: 100 or 300 eptinezumab by IV infusion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Double-Blind Treatment Phase (at baseline): Placebo by IV infusion.&#xD;
For patients outside Japan, at week 12: 100 or 300 eptinezumab by IV infusion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo - 100 mL of 0.9% normal saline, intravenously</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eptinezumab</intervention_name>
    <description>Eptinezumab - solution for infusion, intravenously</description>
    <arm_group_label>Eptinezumab 100 mg</arm_group_label>
    <arm_group_label>Eptinezumab 300 mg</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Lu AG09221</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The patient has a diagnosis of CM as defined by IHS ICHD-3 guidelines confirmed at&#xD;
             screening visit with a history of migraine onset at least 12 months prior to the&#xD;
             Screening Visit.&#xD;
&#xD;
          -  The patient has had a diagnosis of migraine at &lt;50 years of age.&#xD;
&#xD;
          -  The patient has ≥8 migraine days per month for each month within the past 3 months&#xD;
             prior to the Screening Visit.&#xD;
&#xD;
          -  The patient fulfils the following criteria for migraine in prospectively collected&#xD;
             information in the eDiary during the screening period:&#xD;
&#xD;
          -  Migraine occurring on ≥8 days and headache occurring on ≥15 to ≤26 days.&#xD;
&#xD;
          -  The patient has demonstrated compliance with the Headache eDiary by entry of data for&#xD;
             at least 24 of the 28 days following the Screening Visit.&#xD;
&#xD;
          -  The patient is aged ≥18 (≥20 for Taiwan) and ≤75 years at the Screening Visit.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The patient has received any medication targeting the calcitonin gene-related peptide&#xD;
             (CGRP) pathway as preventive treatment of migraine.&#xD;
&#xD;
          -  The patient has confounding and clinically significant pain syndromes, (for example,&#xD;
             fibromyalgia, chronic low back pain, complex regional pain syndrome).&#xD;
&#xD;
          -  The patient has a diagnosis of acute or active temporomandibular disorder.&#xD;
&#xD;
          -  The patient has a history or diagnosis of chronic tension-type headache, hypnic&#xD;
             headache, cluster headache, hemicrania continua, new daily persistent headache, or&#xD;
             unusual migraine subtypes such as hemiplegic migraine (sporadic and familial),&#xD;
             ophthalmoplegic migraine, migraine with brainstem aura and migraine with neurological&#xD;
             accompaniments that are not typical of migraine aura (diplopia, altered consciousness,&#xD;
             or long duration).&#xD;
&#xD;
          -  The patient has a lifetime history of psychosis, bipolar mania, or dementia.&#xD;
&#xD;
          -  Patients with other psychiatric conditions whose symptoms are not controlled or who&#xD;
             have not been adequately treated for a minimum of 6 months prior to screening are also&#xD;
             excluded.&#xD;
&#xD;
          -  The patient has a history of clinically significant cardiovascular disease, including&#xD;
             uncontrolled hypertension, vascular ischaemia or thromboembolic events (for example,&#xD;
             cerebrovascular accident, deep vein thrombosis, or pulmonary embolism).&#xD;
&#xD;
        Other inclusion and exclusion criteria may apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Email contact via H. Lundbeck A/S</last_name>
    <role>Study Director</role>
    <affiliation>LundbeckClinicalTrials@Lundbeck.com</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Email contact via H. Lundbeck A/S</last_name>
    <phone>+45 36301311</phone>
    <email>LundbeckClinicalTrials@Lundbeck.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chinese PLA General Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100853</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The First Hospital of Jilin University</name>
      <address>
        <city>Changchun</city>
        <zip>130021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Affiliated Hospital of Guizhou Medical University</name>
      <address>
        <city>Guiyang</city>
        <zip>550000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Union Hospital Tongji Medical College Huazhong University of Science and Technology</name>
      <address>
        <city>Wuhan</city>
        <zip>430022</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pineo Medical Ecosystem</name>
      <address>
        <city>Tbilisi</city>
        <zip>0114</zip>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Aversi Clinic LTD</name>
      <address>
        <city>Tbilisi</city>
        <zip>0160</zip>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Iwate Medical University Uchimaru Medical Center</name>
      <address>
        <city>Morioka</city>
        <state>Iwate</state>
        <zip>020-8505</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sendai Headache and Cranial Nerves Clinic</name>
      <address>
        <city>Sendai-Shi Taihaku-Ku</city>
        <state>Miyagi</state>
        <zip>982-0014</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nagamitsu Clinic</name>
      <address>
        <city>Hofu</city>
        <state>Yamaguti</state>
        <zip>7470802</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Moriyama Neurological Center Hospital</name>
      <address>
        <city>Edogawa-ku</city>
        <zip>134-0085</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>DOI Clinic Internal Medicine</name>
      <address>
        <city>Hirosima Naka-ku</city>
        <zip>730-0031</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Atsuchi Neurosurgery Hospital</name>
      <address>
        <city>Kagoshima-shi</city>
        <zip>892-0842</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ikeda Neurosurgery</name>
      <address>
        <city>Kasuga City</city>
        <zip>816-0824</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Jinnouchi Neurosurgery Clinic</name>
      <address>
        <city>Kasuga-shi</city>
        <zip>816-0802</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shin Matsudakai Atago Hospital</name>
      <address>
        <city>Kochi-shi</city>
        <zip>780-0051</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tatsuoka Neurology Clinic</name>
      <address>
        <city>Kyoto Shimojo-ku</city>
        <zip>680-8811</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mito Kyodo General Hospital</name>
      <address>
        <city>Mito-shi</city>
        <zip>310-0015</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tominaga Hospital</name>
      <address>
        <city>Naniwa-ku</city>
        <zip>5560017</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tokyo headache clinic</name>
      <address>
        <city>Shibuya-ku</city>
        <zip>151-0051</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Japanese Red Cross Shizuoka Hospital</name>
      <address>
        <city>Shizuoka-shi</city>
        <zip>420-0853</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Toyota Memorial Hospital</name>
      <address>
        <city>Toyota-shi</city>
        <zip>471-8513</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Inje University Ilsan Paik Hospital</name>
      <address>
        <city>Goyang-si</city>
        <state>Gyeonggido</state>
        <zip>10380</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chungnam National University Hospital</name>
      <address>
        <city>Daejeon</city>
        <zip>35015</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hallym University Dongtan Sacred Heart Hospital</name>
      <address>
        <city>Gyeonggi-do</city>
        <zip>18450</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nowon Eulji Medical Center, Eulji University</name>
      <address>
        <city>Seoul</city>
        <zip>01830</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kangbuk Samsung Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03181</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Severance Hospital Yonsei University Health System - PPDS</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center - PPDS</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Vall d'Hebron - PPDS</name>
      <address>
        <city>Barcelona</city>
        <zip>8035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario HM Sanchinarro - CIOCC</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario de Valladolid</name>
      <address>
        <city>Valladolid</city>
        <zip>47005</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario Lozano Blesa</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tri-Service General Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>11490</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>China</country>
    <country>Georgia</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Spain</country>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>June 4, 2021</study_first_submitted>
  <study_first_submitted_qc>June 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 10, 2021</study_first_posted>
  <last_update_submitted>October 20, 2021</last_update_submitted>
  <last_update_submitted_qc>October 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

